Reversible Cardiomyopathy Associated with Autoimmune Polyendocrine Syndrome Type II

Yusuf Karavelioglu, Ahmet Baran, Hekim Karapınar, Zekeriya KüçükDurmuş and Ahmet Yılmaz

Abstract

Recovery of the ventricular function in a patient with cardiomyopathy is very rare. Autoimmune polyendocrine syndrome is also very rare. We herein report a case of reversed cardiomyopathy associated with autoimmune polyendocrine syndrome type II (Schmidt’s syndrome) composed of Addison’s disease, vitiligo and Hashimoto’s thyroiditis. The ventricular function and size were reversed following the administration of suitable hormone replacement therapy for polyendocrine syndrome.

Key words: autoimmune polyendocrine syndrome II, adrenal insufficiency, hypothyroidism, vitiligo, cardiomyopathy, Takotsubo, cardiomyopathy

(DOI: 10.2169/internalmedicine.52.7188)

Introduction

Autoimmune polyendocrine syndrome type II (APS-II, Schmidt’s syndrome) is a rare, immune-mediated endocrinopathy accompanied by autoimmune Addison’s disease, autoimmune thyroid disease and/or type 1 diabetes mellitus (1). In many cases of autoimmune polyendocrine syndrome, autoimmune Addison’s disease is associated with other autoimmune diseases, the most frequent being Hashimoto’s thyroiditis. However, all three components (Addison’s disease, thyroid disease and type 1 diabetes mellitus) are seen together in 10-20% of cases. Other rare components of the disease include additional autoimmune diseases such as vitiligo, alopecia, hypergonadotropic hypogonadism, chronic atrophic gastritis, chronic hepatitis and hypophysitis. Although it is not included in the definition criteria of the syndrome, cardiac involvement may be seen in rare cases (1). We herein report the case of a patient with APS-II that included Addison’s disease, vitiligo and Hashimoto’s thyroiditis who developed cardiomyopathy that recovered following the administration of appropriate endocrine therapy.

Case Report

A 36-year-old woman was admitted to our hospital with fatigue, nausea and vomiting. She had experienced fatigue for several months and nausea and vomiting for several weeks. Her medical history revealed that she had suffered from vitiligo for 20 years and had been followed up in a psychiatry clinic for bipolar disorder. There were no overt endocrine or cardiovascular diseases in her family history. The patient was a non-smoker and non-alcohol consumer. She had three living children and no menstrual irregularities. She was cooperative and oriented but cachectic and exhausted. She weighed 45 kilograms (kg) and was 165 centimeters (cm) in height. On inspection, extensive hyperpigmentation of the skin was noted with areas of vitiligo on the hands, face and feet. No edema was observed and the patient’s skin was dry. Her blood pressure was 90/60 mmHg, her heart rate was 60 beats per minute and rhythmic, her respiratory rate was 13 breaths/minute and her SpO2 was 98%. Other system examinations were unremarkable. Chest X-ray revealed cardiac enlargement, clear pulmonary areas and no pleural effusion. A sinus rhythm with T-wave negativity extended to the precordial and extremity leads was ob-

1Department of Cardiology, Çorum State Hospital, Turkey, 2Department of Internal Medicine, Çorum State Hospital, Turkey and 3Department of Cardiology, Cumhuriyet University, Medical School, Turkey

Received for publication December 25, 2011; Accepted for publication January 14, 2013
Correspondence to Dr. Hekim Karapınar, drhekim@yahoo.com
served on electrocardiography (ECG).

Biochemical analyses revealed hyponatremia (124 meq/L) and hyperkalemia (7.5 meq/L). The serum urea and creatinine levels were normal (Table). The serum troponin I level was also normal and the level of N-terminal probrain natriuretic peptide (NT-proBNP) was 135 pg/mL. Because the elevated potassium level did not decrease despite the administration of medical therapy, the patient was admitted to the intensive care unit where she underwent dialysis for a single session. The potassium level returned to the normal range after dialysis. The patient had also fatigue despite normal electrolyte levels. A blood sample analysis showed a low serum cortisol level (<1 μg/dL, normal range: 5-25 μg/dL, at 8 a.m.) and an elevated adrenocorticotropic hormone level (1,250 pg/mL). Dynamic magnetic resonance imaging (MRI) of the pituitary gland was normal. MRI of the abdomen, including the adrenal glands, was normal. Serology for human immunodeficiency virus and the hepatitis B and C viruses was normal. A purified protein derivative (PPD) tuberculin skin test was non-reactive. The patient was diagnosed with Addison’s disease based on her clinical and laboratory findings.

The thyroid-stimulating hormone (TSH) level was elevated (31 mIU/L, normal range: 0.4-4.2 mIU/L), the free triiodothyronine and free thyroxin levels were in the normal ranges and the anti-thyroid peroxidase antibody titer was high (942 U/mL). Thyroid gland ultrasound showed a normal-sized, heterogeneous thyroid gland without nodules. The ultrasound findings were compatible with a diagnosis of Hashimoto’s thyroiditis, which was made based on these findings.

Taking the presence of vitiligo, Addison’s disease and Hashimoto’s thyroiditis into consideration, the patient was diagnosed with APS II and evaluated for other components of APS type II. The presence of type 1 diabetes mellitus was assessed according to the plasma fasting glucose and glycolized hemoglobin 1c (HbA1c) levels and glucose tolerance tests; however, the results did not support a type 1 dia-

<table>
<thead>
<tr>
<th>Table. Laboratory Results at the Time of Admission and Follow-up</th>
<th>Baseline</th>
<th>1st month</th>
<th>3rd month</th>
<th>1st year</th>
<th>Normal values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucose, mg/dL</td>
<td>102</td>
<td>73</td>
<td>75</td>
<td>65</td>
<td>70-100</td>
</tr>
<tr>
<td>HbA1c, mg/dL</td>
<td>5.33</td>
<td>4.9</td>
<td>5.6</td>
<td>5.4</td>
<td>4-6.1</td>
</tr>
<tr>
<td>Urea, mg/dL</td>
<td>45</td>
<td>42</td>
<td>39</td>
<td>40</td>
<td>0-50</td>
</tr>
<tr>
<td>Creatinine, mg/dL</td>
<td>0.9</td>
<td>0.8</td>
<td>0.7</td>
<td>0.8</td>
<td>0.2-1.3</td>
</tr>
<tr>
<td>Sodium, mmol/L</td>
<td>127</td>
<td>135</td>
<td>135</td>
<td>139</td>
<td>134-148</td>
</tr>
<tr>
<td>Potassium, mmol/L</td>
<td>7.5</td>
<td>3.7</td>
<td>3.8</td>
<td>4.2</td>
<td>3.5-5.5</td>
</tr>
<tr>
<td>Chloride mmol/L</td>
<td>104</td>
<td>101</td>
<td>97</td>
<td>100</td>
<td>90-108</td>
</tr>
<tr>
<td>Calcium, mg/dL</td>
<td>7.6</td>
<td>8.2</td>
<td>8.2</td>
<td>8.3</td>
<td>8-11</td>
</tr>
<tr>
<td>Phosphor, mg/dL</td>
<td>3.5</td>
<td>-</td>
<td>-</td>
<td>4.1</td>
<td>2.5-4.5</td>
</tr>
<tr>
<td>Thyroid-stimulating hormone, mIU/L</td>
<td>31</td>
<td>3.6</td>
<td>3.1</td>
<td>2.3</td>
<td>0.4-4.2</td>
</tr>
<tr>
<td>Free triiodothyronine, pg/mL</td>
<td>3.73</td>
<td>4.18</td>
<td>4.09</td>
<td>3.62</td>
<td>2.3-4.2</td>
</tr>
<tr>
<td>Free thyroxine, ng/dL</td>
<td>1.08</td>
<td>1.50</td>
<td>1.45</td>
<td>1.53</td>
<td>0.72-1.56</td>
</tr>
<tr>
<td>Alanine transaminase, U/L</td>
<td>34</td>
<td>25</td>
<td>24</td>
<td>22</td>
<td>0-50</td>
</tr>
<tr>
<td>Aspartate transaminase, U/L</td>
<td>16</td>
<td>15</td>
<td>20</td>
<td>21</td>
<td>0-50</td>
</tr>
<tr>
<td>Creatine kinase, U/L</td>
<td>65</td>
<td>70</td>
<td>73</td>
<td>71</td>
<td>25-170</td>
</tr>
<tr>
<td>Creatine kinase-MB fraction, U/L</td>
<td>20</td>
<td>15</td>
<td>16</td>
<td>18</td>
<td>5-25</td>
</tr>
<tr>
<td>Lactate Dehydrogenase IU/L</td>
<td>357</td>
<td>330</td>
<td>300</td>
<td>310</td>
<td>240-480</td>
</tr>
<tr>
<td>Troponin T, μg/L</td>
<td>&lt;0.01</td>
<td>-</td>
<td>-</td>
<td>&lt;0.01</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Cortisol, μg/dL</td>
<td>&lt;1</td>
<td>1.1</td>
<td>3.1</td>
<td>3</td>
<td>5.0-25.0</td>
</tr>
<tr>
<td>Adrenocorticotropic hormone, pg/mL</td>
<td>&gt;1,250</td>
<td>38</td>
<td>41</td>
<td>33</td>
<td>10-52</td>
</tr>
<tr>
<td>Hemoglobin g/dL</td>
<td>10.6</td>
<td>10.9</td>
<td>11.4</td>
<td>12.4</td>
<td>11.5-16.5</td>
</tr>
<tr>
<td>Hematocrit, %</td>
<td>35.1</td>
<td>36.4</td>
<td>38.5</td>
<td>41</td>
<td>37-47</td>
</tr>
<tr>
<td>Parathormone, pg/mL</td>
<td>76.5</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>10-70</td>
</tr>
<tr>
<td>Prolactin, ng/mL</td>
<td>12.06</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3.5-20</td>
</tr>
<tr>
<td>Follicle-stimulating hormone, mIU/mL</td>
<td>20.2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>6-26</td>
</tr>
<tr>
<td>Luteinizing hormone, mIU/mL</td>
<td>17</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>20-75</td>
</tr>
<tr>
<td>Estradiol, pg/mL</td>
<td>98</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>19-140</td>
</tr>
<tr>
<td>Vitamin B12, pg/mL</td>
<td>362</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>191-663</td>
</tr>
<tr>
<td>Folate, ng/mL</td>
<td>11.7</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3-17.5</td>
</tr>
<tr>
<td>Albumin, g/dL</td>
<td>3.9</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3.5-5.0</td>
</tr>
<tr>
<td>Anti-thyroid peroxidase antibody, U/mL</td>
<td>942</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0-30</td>
</tr>
<tr>
<td>Anti-thyroglobulin antibody, U/mL</td>
<td>37</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>&lt;20</td>
</tr>
</tbody>
</table>
A cardiovascular examination was performed to assess cardiac involvement. Control ECG performed after dialysis revealed a sinus rhythm with persistent T-wave negativity on the precordial and extremity leads (ECG, Fig. 1A). Echocardiography revealed an enlarged left ventricle with a depressed systolic function, akinesis of the anterior, apical and septal segments and hypokinesis of the other segments (Fig. 2A, B) with mild mitral and tricuspid regurgitation. The estimated left ventricular end diastolic pressure was slightly elevated (E/e'=12). Mild spontaneous echo contrast was noted in the left ventricular cavity.

The patient was administered prednisolone at a dose of 7.5 mg, fludrocortisone at a dose of 0.1 mg and levothyroxine at a dose of 50 mcg daily due to the high TSH levels and clinical findings of hypothyroidism such as depression. Her complaints and findings began to resolve after the first week. On the 1st month follow-up visit, the patient’s complaints were alleviated, and the New York Heart Association functional capacity improved from class II to class I. On the 3rd month follow-up visit, the ECG and echocardiography findings were found to be completely recovered (Figs. 1B, 2C, D), while the estimated left ventricular end diastolic pressure (E/e'=6) and NT-proBNP levels (95 pg/mL) were normal. While under daily maintenance therapy with 5 mg of prednisolone, 100 mcg of levothyroxine and 0.1 mg of fludrocortisone at the 3rd month follow-up visit, the patient’s blood pressure was 115/75 mmHg, her heart rate was 63 beats per minute and her blood levels of serum sodium, potassium, glucose, cortisol, adrenocorticotropic hormone and thyroid-stimulating hormone were normal. Her body weight had increased from 45 kg to 55 kg at the 3rd month follow-up visit and to 65 kg at the 1st year follow-up visit. The patient was completely asymptomatic while under the maintenance therapy. The baseline and follow-up biochemical and hormonal analysis results of the blood samples are shown in Table.
Discussion

We herein presented a case of APS-II with cardiomyopathy that completely recovered with appropriate treatment. In most cases of APS-II, autoimmune Addison’s disease is associated with Hashimoto’s thyroiditis, whereas three components (Addison’s disease, thyroid disease and type 1 diabetes mellitus) are seen together in 10-20% of cases. According to recent epidemiological data, the frequency of APS-II is estimated to be 4-5 cases per 100,000 individuals in the general population (2). Other autoimmune diseases such as vitiligo, alopecia, hypergonadotropic hypogonadism, chronic atrophic gastritis, chronic hepatitis and hypophysitis are minor components that are likely to accompany the syndrome. The present patient had Addison’s disease, Hashimoto’s thyroiditis and vitiligo.

Left ventricular dysfunction was observed in the present case. This has rarely been reported in the literature and is not included in the definition or classification criteria of APS (1). Myocardial systolic dysfunction has been reported to be reversible in most cases reported in the literature. Left ventricular systolic dysfunction was reported to manifest as apical ballooning (Takotsubo cardiomyopathy, TC) in one case (3) in which the patient was observed to have ST-segment elevation and elevated levels of myocardial necrosis markers at the time of hospital admission, although the ventricular function recovered after a few days, as in other apical ballooning cases. TC is characterized by acute onset and quickly reversible left ventricular apical wall motion abnormalities with chest symptoms, ST-segment elevation and T-wave inversion on ECG, minimal-moderate myocardial enzymatic release and no significant stenosis on coronary angiography (CAG). Ukita et al. reported another case of a patient with acute adrenal insufficiency and TC (4). We did not consider our patient to have TC, although the cardiac involvement was similar, because TC typically exhibits an acute course and occurs in postmenopausal women. However, in our case, the patient’s clinical course was chronic and she was in a reproductive period. In addition, TC presents with mild-moderate cardiac enzyme elevation; however, these markers were normal in our patient. Furthermore, the cardiac function recovers over a short time period (days to a couple of weeks) in patients with TC, while our patient’s cardiac function recovered in weeks to months. Finally, in this case, recovery was observed only after the administration of appropriate hormone replacement therapy and did not occur spontaneously, as in patients with TC. The previously reported case is unlike the recent case with respect to the acute clinical course. However, the effects of chronic stress (e.g., adrenal insufficiency) on the cardiac function are unknown and should be evaluated in prospective studies.

Another patient with APS-II presented with heart failure after delivery and was diagnosed with peripartum cardiomyopathy (5). The authors reported that the patient recovered at the first month follow-up after the administration of hormone replacement treatment (5). Unfortunately, another reported patient with worsened heart failure was referred for cardiac transplantation (6). In addition, pulmonary hypertension was observed in an APS-II case reported by Saliba et al. (7), and right ventricular dysfunction was observed in an isolated adrenocorticotropic hormone deficiency case reported by Shimizu et al. (8). Therefore, APS-II not only may be associated with left ventricular systolic dysfunction, but also may exhibit myocardial and vascular involvement. In the present case, the patient’s pulmonary blood pressure calculated via tricuspid regurgitation was normal. There were no signs of right ventricular involvement.

Apart from APS-II, the development of left ventricular dysfunction in patients with pure adrenocorticotropic hormone deficiency (8-10) might originate from adrenal gland dysfunction. The contribution of electrolyte imbalances, which were noted at the time of hospital admission in the present case, to the development of transient left ventricular dysfunction may be a possible factor. Severe hyponatremia increases the intracellular calcium concentrations by inducing sodium and calcium ion channel dysfunction in the cell membrane, which might be reflected as myocardial dysfunction in the clinical picture. The fact that the hyponatremia observed in the present case was not very severe and returned to a normal level in the early term reduces this possibility. Glucocorticoids play important roles in myocardial contraction. Impaired calcium uptake in the sarcoplasmic reticulum and decreased microsomal phosphorylase activity in adrenalectomized rats are associated with myocardial dysfunction (11, 12). Furthermore, it has also been reported that intracellular calcium concentrations are affected by glucocorticoid hormones that bind to cardiac ion channels (13). Therefore, we suggest that the reversible ventricular wall motion abnormalities noted in the present case might have resulted from alterations in intracellular calcium concentrations due to hyponatremia and adrenal insufficiency.

APS is a rare endocrine syndrome. Cardiac signs have been reported, although rarely. While the causes of APS have not yet been clearly established, cardiac involvement presents with systolic dysfunction of the myocardium rather than dysfunction in the conduction system. For patients with APS who are evaluated to have diagnoses of cardiac failure or myocardial infarction, it is beneficial to keep this reversible picture in mind. Speculations on its etiology will become clearer with the identification of more cases.

The authors state that they have no Conflict of Interest (COI).

References

2. Laureti S, Vecchi L, Santeusanio F, Falorni A. Is the prevalence of

© 2013 The Japanese Society of Internal Medicine
http://www.naika.or.jp/imonline/index.html